Answers are grounded in this paper and cite their sources.
Review uncovers novel small-molecule EGFR inhibitors and structural design strategies in breast cancer, highlighting chemical approaches to overcome acquired therapeutic resistance.
Breast cancer continues to be one of the top causes of cancer death globally, with triple‐negative breast cancer (TNBC) being the most aggressive variety as it has a much poorer prognosis, strong propensity for metastases, and fewer effective targeted therapies available. The increased expression of the epidermal growth factor receptor (EGFR) is essential for cancer cell growth, survival, migration, and drug resistance making EGFR a good target for therapy. However, the effectiveness of EGFR inhibitors has been limited because of heterogeneity of tumors, low occurrence of activating EGFR mutations, and activity of compensatory pathways. This mini‐review aims to summarize new findings on the design of small molecules that inhibit EGFR including pyrimidine‐5‐carbonitrile, thiazolyl‐pyrazolines, quinoxaline, quinazoline–sulfonamide hybrids, xanthine–chalcone conjugates, aminoquinolines, and pyridazine analogues. Their pharmacological properties, interactions with EGFR in silico and important structural characteristics responsible for their therapeutic action will also be discussed. Possible approaches for overcoming acquired resistance, including covalent and allosteric inhibitors, dual‐acting compounds, and combination therapies will be presented here.
No takes yet. Share an insight, caveat, or question.
Shrivastava et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: